Clinical trials
Completed Phase 3 Head and Neck Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
91 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 7 |
| 2006 | 4 |
| 2007 | 4 |
| 2008 | 7 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 1 |
| 2020 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 91 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Radiation Therapy Oncology Group | 11 |
| Eastern Cooperative Oncology Group | 5 |
| Sanofi | 4 |
| Alliance for Clinical Trials in Oncology | 3 |
| Boehringer Ingelheim | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Amgen | 2 |
| Merck Sharp & Dohme LLC | 2 |
| NCIC Clinical Trials Group | 2 |
| Adlai Nortye Biopharma Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Head and Neck Neoplasms | 91 |
| Squamous Cell Carcinoma of Head and Neck | 39 |
| Carcinoma, Squamous Cell | 8 |
| Neoplasms | 8 |
| Stomatitis | 7 |
| Mucositis | 6 |
| Radiation Injuries | 6 |
| Esthesioneuroblastoma, Olfactory | 5 |
| Salivary Gland Neoplasms | 5 |
| Oropharyngeal Neoplasms | 4 |
Trials
Showing 1 to 25 of 91. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.